AdvanCell
Develops lead-212 targeted alpha therapies to treat cancer
$315MSeries D
Role not disclosedSH
SV Health Investors
Activity from announced rounds
Activity in this selectionflintlock-capital-10c4d83c
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $463M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionDraig Therapeutics
Developing transformative, best-in-class neuropsychiatric therapies
$65MSeries B
Role not disclosedTRex Bio
Develops precision immunoregulatory medicines based on tissue Treg biology
$50MUndisclosed
Role not disclosedPayMedix
Provides healthcare financing and payments solutions
$33MUndisclosed
Role not disclosed